Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane

Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast Cancer

The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.

This is a study on volunteers to determine effective dose of dexrazoxane in degrading Topoisomerase 2 b in human blood samples. Each participant will receive one dose of dexrazoxane. Blood samples will be collected to determine the time course and degradation of Topoisomerase 2b and Topoisomerase 2a

Inclusion Criteria:

• Women,
• Age 18-65,
• Not pregnant, Not currently breast feeding
• No current illness,

Exclusion Criteria:

• Pregnancy, currently breast feeding
• Current illness,
• History of cardiac, or renal disease